- Home
- PZZA vs IMTX Comparison
PZZA vs IMTX Comparison
Compare PZZA & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PZZA | IMTX |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | PZZA | IMTX |
|---|---|---|
| Price | $42.03 | $10.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 5 |
| Target Price | ★ $49.44 | $19.25 |
| AVG Volume (30 Days) | ★ 2.5M | 640.0K |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $2,086,399,000.00 | $99,445,031.00 |
| Revenue This Year | $4.45 | N/A |
| Revenue Next Year | $0.93 | $13.52 |
| P/E Ratio | $36.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.16 | $3.30 |
| 52 Week High | $55.74 | $11.25 |
Technical Indicators
Market Signals| Indicator | PZZA | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 45.32 | 57.57 |
| Support Level | $38.40 | $9.84 |
| Resistance Level | $42.68 | $11.34 |
| Average True Range (ATR) | 2.43 | 0.78 |
| MACD | 0.23 | 0.07 |
| Stochastic Oscillator | 34.18 | 78.93 |
Price Performance
Historical ComparisonAbout PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.